Literature DB >> 21679919

Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma.

Tetsuhiro Owaki1, Masataka Matsumoto, Hiroshi Okumura, Yasuto Uchicado, Yoshiaki Kita, Tetsuro Setoyama, Ken Sasaki, Toshihide Sakurai, Itaru Omoto, Mario Shimada, Fuminori Sakamoto, Heiji Yoshinaka, Sumiya Ishigami, Shinichi Ueno, Shoji Natsugoe.   

Abstract

BACKGROUND: Recently, neoadjuvant chemoradiation therapy (CRT) has been introduced for treatment of esophageal squamous cell carcinoma (ESCC). This study was performed to investigate the usefulness of endoscopic ultrasonography (EUS) in comparison with EUS findings before and after CRT, and histologic findings.
METHODS: There were 33 patients with potentially resectable ESCC who underwent neoadjuvant CRT. Preoperative EUS and histologic findings were compared. EUS criteria were established on the basis of low and high echoic regions. Resected specimens were examined by hematoxylin-eosin, azan, and cytokeratin immunohistochemical staining.
RESULTS: Azan and cytokeratin staining clearly delineated fibrous changes and residual tumor. Low echoic regions corresponded to residual tumor and high echoic spots corresponded to fibrosis. All 12 patients classified as grade 1 on EUS diagnosis had histologic grade 1 tumors. Nineteen of 21 cases that presented with high echo were grade 2 or 3. The prognosis according to EUS diagnosis was similar to the histologic effect.
CONCLUSIONS: Preoperative EUS findings reflected the histologic effect after neoadjuvant CRT. EUS is a useful tool to assess the effect for CRT and to predict the prognosis in ESCC patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21679919     DOI: 10.1016/j.amjsurg.2011.01.027

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

1.  Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.

Authors:  Hiroshi Okumura; Yasuto Uchikado; Masataka Matsumoto; Tetsuhiro Owaki; Yoshiaki Kita; Itaru Omoto; Ken Sasaki; Toshihide Sakurai; Tetsuro Setoyama; Bunpei Nabeki; Daisuke Matsushita; Sumiya Ishigami; Yoshiyuki Hiraki; Masayuki Nakajo; Shoji Natsugoe
Journal:  Int J Clin Oncol       Date:  2012-02-18       Impact factor: 3.402

2.  Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.

Authors:  Susanne Blank; Florian Lordick; Franz Bader; Maria Burian; Martin Dobritz; Lars Grenacher; Karen Becker; Wilko Weichert; Rupert Langer; Leila Sisic; Annika Stange; Dirk Jäger; Markus Büchler; Thomas Bruckner; Jörg Siewert; Katja Ott
Journal:  Gastric Cancer       Date:  2014-04-11       Impact factor: 7.370

3.  Different strategy of salvage esophagectomy between residual and recurrent esophageal cancer after definitive chemoradiotherapy.

Authors:  Yusuke Taniyama; Tadashi Sakurai; Takahiro Heishi; Hiroshi Okamoto; Chiaki Sato; Shota Maruyama; Yu Onodera; Hirotaka Ishida; Michiaki Unno; Takashi Kamei
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Factors Predicting Effectiveness of Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.

Authors:  Yu Ohkura; Masaki Ueno; Toshiro Iizuka; Shusuke Haruta; Tsuyoshi Tanaka; Harushi Udagawa
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

5.  Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling.

Authors:  Patricia Martin-Romano; Belén P Solans; David Cano; Jose Carlos Subtil; Ana Chopitea; Leire Arbea; Maria Dolores Lozano; Eduardo Castanon; Iosune Baraibar; Diego Salas; Jose Luis Hernandez-Lizoain; Iñaki F Trocóniz; Javier Rodriguez
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

6.  Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery.

Authors:  Min Kong; Jianfei Shen; Chao Zhou; Haihua Yang; Baofu Chen; Chengchu Zhu; Gongchao Wang
Journal:  Ann Transl Med       Date:  2020-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.